Abiraterone in metastatic prostate cancer without previous chemotherapy - Wikidata - wikimedia - TriplyDB

Abiraterone in metastatic prostate cancer without previous chemotherapy

Abiraterone in metastatic prostate cancer without previous chemotherapy

http://www.wikidata.org/entity/Q24612084

about

Emerging molecularly targeted therapies in castration refractory prostate cancer Immunobiology and immunotherapy in genitourinary malignancies Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Galeterone for the treatment of advanced prostate cancer: the evidence to date The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers Splice Variants of Androgen Receptor and Prostate Cancer An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer Molecular signaling involving intrinsically disordered proteins in prostate cancer Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Clonal origin and spread of metastatic prostate cancer A primer on tumour immunology and prostate cancer immunotherapy Contemporary Management of Prostate Cancer Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Sequence of treatment in locally advanced and metastatic renal cell carcinoma Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy Targeting molecular resistance in castration-resistant prostate cancer Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy DNA damage response and prostate cancer: defects, regulation and therapeutic implications Immunotherapy for prostate cancer: recent developments and future challenges Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Abiraterone in the treatment of metastatic castration-resistant prostate cancer Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer Current clinical challenges in prostate cancer Targeting the androgen receptor with steroid conjugates Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer Chemotherapy and its evolving role in the management of advanced prostate cancer Targeting the androgen receptor in prostate and breast cancer: several new agents in development Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

P2860

Q21284745-9B7FB83E-9C50-416B-B581-A8648C1691CB Q26738668-8EA74798-CA19-4305-9010-FC827D210969 Q26739708-A1319423-8C28-4B8F-BD45-563ADE507827 Q26739887-D7EDCE89-7757-483C-9090-6B55DAA99751 Q26740401-3F18775C-C48C-465C-8496-61E2D7946F97 Q26740592-82BD639F-935B-47DB-B70E-1E3F55987876 Q26744431-7B1EF2C5-E05A-4972-BCEB-269E9ED47300 Q26747089-BA0BE131-0F8A-481A-BF1E-B14962A90B25 Q26747699-1B3BE2D3-5556-41C0-8480-7E213EFEEBC0 Q26747782-FE370E0C-CF49-4D89-BEBD-32DD7E8B21C8 Q26750620-0D539F95-AB5E-46AB-97CD-1FDFF24B3A55 Q26751237-2AE27964-654D-4C55-AADE-AB6B9D7332C6 Q26752873-C0953FEC-1A60-4D6E-8524-2EFA95986B92 Q26765697-E0F8D3FB-81E7-4625-83E5-D924B33884B8 Q26767456-F09238CF-6D6D-4237-9C56-3D78878D2423 Q26772883-0FC90CE3-186A-46B5-AF51-5F7F9C73B1EF Q26773634-D0086139-2647-4FD6-982A-9780AF6D699B Q26773653-8F30EE42-2301-4130-B199-A556E4E0651A Q26774221-000BC99A-1220-4514-A9F1-F939C994DD0E Q26777163-0991E26C-6E9D-4FA6-9485-7431B0F794FC Q26777310-4EEC6047-8B16-48D4-A283-382E7DED2EFB Q26786543-36DEBEB8-2530-4260-84F0-B8B9D4DBB4D4 Q26795445-F85CE0A0-4137-49FB-89CF-A0B8840A8022 Q26825053-130310FA-5FBB-4EDA-A97B-AD4F2CC4A59D Q26829155-9FD4D2F3-2453-4842-B11A-D382DB7D5BDB Q26852388-966B7B65-64F0-4B47-B52C-1249B358A3AE Q26852544-C5C1C39D-422C-4C5C-82BB-BE1C08895B34 Q26853635-6523CE3A-E279-4717-B91E-54B942FEA8CC Q26858922-DC84D4D6-D4D4-45D8-B15A-141F203D2C28 Q26861575-85D14BD5-27AF-485D-B2F6-5F6320575A01 Q26865701-0F640D5C-39AE-4A1B-872F-A50068768D5F Q26866036-6EF02994-25ED-4E77-BF32-D0FA40239107 Q26995692-E8C5BB7C-5E8D-42C8-A9B0-85102B3B2E72 Q27002342-81EFE9F4-066A-43F8-AA27-EDDC672F4443 Q27008883-9F397738-B842-4580-BFF6-3EC326E68DC1 Q27009424-784AEDEC-07C4-4683-9035-73D789289635 Q27010542-72E80031-9F71-4BF7-94FF-F9665CA12DA8 Q27011642-EDD32A70-7147-4CC5-A7E8-B1984DAC44AB Q27022567-4BBC774E-A1A1-4B5F-AB66-76511A8AF824 Q27022715-31E80404-33B0-4BFA-A395-CAB641108A87

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

http://www.wikidata.org/entity/Q24612084

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Abiraterone in metastatic prostate cancer without previous chemotherapy

@ast

Abiraterone in metastatic prostate cancer without previous chemotherapy

@en

Abiraterone in metastatic prostate cancer without previous chemotherapy

@nl

type

label

Abiraterone in metastatic prostate cancer without previous chemotherapy

@ast

Abiraterone in metastatic prostate cancer without previous chemotherapy

@en

Abiraterone in metastatic prostate cancer without previous chemotherapy

@nl

prefLabel

Abiraterone in metastatic prostate cancer without previous chemotherapy

@ast

Abiraterone in metastatic prostate cancer without previous chemotherapy

@en

Abiraterone in metastatic prostate cancer without previous chemotherapy

@nl

P1433

Q24612084-037C5447-C0D3-4885-821E-22347DE5BB7B

P1476

Q24612084-15B2FE40-16F4-437C-B22B-577C363159F8

P2093

Q24612084-02FDC780-2463-47FD-B608-91C4FFB38086

Q24612084-583B2BF4-F683-4B95-8291-3BADAAFFFB9B

Q24612084-5BBD12DE-525B-44CA-9263-D350371B7F0F

Q24612084-64CAAB21-D9B0-4E62-BEA4-48872BFE2215

Q24612084-682C696E-5E6A-4E1C-B74B-48086B534B82

Q24612084-6917FD26-0983-434C-B185-61FB5DE4C029

Q24612084-6F0ECF0D-398A-4991-BAF2-9A5CC7BAAB09

Q24612084-77A4C415-A357-421E-A380-5C5698188A67

Q24612084-7F4A8574-6BB7-4B2F-B8E5-10126F2B5811

Q24612084-8C501AF9-1D60-448D-A809-328A02339B21

P2860

Q24612084-01B5FD93-D41F-4B53-A919-076BF8FD12B1

Q24612084-02725DEF-4B70-43B8-8A10-C7086FE899AA

Q24612084-09EE3167-C63C-428F-9E03-C28BDB9F2B0B

Q24612084-172356AD-953C-417E-AC9E-04573FD408FC

Q24612084-178C3E4E-37B0-4387-BA9B-618DA04DB845

Q24612084-207D3156-35C1-4E6F-8F4F-43323E46EF8D

Q24612084-271487B8-F1FC-4FEE-A492-3348F8D0E75C

Q24612084-3216FBE4-299D-4DCA-B3DB-A858474B261F

Q24612084-4B536ADB-1D5A-4FB9-A089-58A270AD7B58

Q24612084-6435BC9A-1C28-4883-8BFA-4A95B57A6F18

P304

Q24612084-CD0EBBB2-A08F-4740-A7FF-AEC540AF89C5

P31

Q24612084-B1AEA105-895A-4808-BA38-8DD58C86710B

P3181

Q24612084-77189086-6FC6-44B4-98E7-FE394BE5DA0F

P356

Q24612084-CC01D22B-12C1-4DB0-917F-4EB2E0B1D189

P407

Q24612084-B319B8A6-93DB-4B16-A914-3D64104D5B9F

P433

Q24612084-5597E4D4-FDC3-434C-BADF-DC6C5DFCBA36

P478

Q24612084-38794F09-7D9F-4808-82B2-65A8AB335FE1

P50

Q24612084-3D1069DA-F5B4-43B2-B30B-834050C56F41

Q24612084-463437D9-5A00-4632-8CD7-212BFEF6F573

Q24612084-D39EF5D5-769F-4006-BCC1-EE74D7631343

Q24612084-DD9C0D6F-4A10-4F89-9480-D68B9C12628A

Q24612084-F5296A60-B3D1-46BC-8912-A3638A792F2C

Q24612084-FDB9F466-EF93-4544-AE6E-E10C774171C2

P577

Q24612084-564F00B8-8101-43DC-8009-126A14E93B6E

P698

Q24612084-3C556B3F-9D92-42AD-94CB-780B5480665A

P921

Q24612084-9B4EE938-BE9B-4EA9-8260-CFFE270246C6

P932

Q24612084-59BDB07F-B5DF-40B3-A1CE-558CBF9339DD

P3181

P356

P1433

The New England Journal of Medicine

P1476

Abiraterone in metastatic prostate cancer without previous chemotherapy

@en

P2093

Allan Pantuck

http://www.w3.org/2001/XMLSchema#string

Arturo Molina

http://www.w3.org/2001/XMLSchema#string

Celestia S Higano

http://www.w3.org/2001/XMLSchema#string

Charles J Ryan

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Daniel J George

http://www.w3.org/2001/XMLSchema#string

Dirk Schrijvers

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Eric Winquist

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.

P304

138-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

932374

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1209096

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P50

Joan Carles Galcerán

Josep M Piulats

Dana E Rathkopf

Mary-Ellen Taplin

P577

2013-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23228172

http://www.w3.org/2001/XMLSchema#string

P921

P932

3683570

http://www.w3.org/2001/XMLSchema#string